NCT01168310

Brief Summary

This is a randomized, double-blind, multi-dose, parallel group trial which will assess the pharmacodynamic response of fluticasone propionate and formoterol fumarate in subjects with COPD.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
468

participants targeted

Target at P75+ for phase_2 chronic-obstructive-pulmonary-disease

Timeline
Completed

Started Aug 2010

Geographic Reach
1 country

23 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 21, 2010

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 23, 2010

Completed
9 days until next milestone

Study Start

First participant enrolled

August 1, 2010

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2010

Completed
1.2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2011

Completed
Last Updated

May 27, 2013

Status Verified

May 1, 2013

Enrollment Period

Same day

First QC Date

July 21, 2010

Last Update Submit

May 17, 2013

Conditions

Keywords

Pulmonary, Obstructive, lungs, COPD

Outcome Measures

Primary Outcomes (1)

  • Change in forced expiratory volume at one second (FEV1) measured in milliliters by spirometry to assess pharmacodynamic response of fluticasone propionate in combination with formoterol fumarate in subject with COPD

    12 Weeks

Secondary Outcomes (1)

  • Incidence of adverse events (AEs)

    12 Weeks

Study Arms (7)

1

EXPERIMENTAL
Drug: Fluticasone Propionate/Formoterol Fumarate

2

EXPERIMENTAL
Drug: Fluticasone Propionate/Formoterol Fumarate

3

EXPERIMENTAL
Drug: Fluticasone Propionate/Formoterol Fumarate

4

EXPERIMENTAL
Drug: Fluticasone Propionate/Formoterol Fumarate

5

EXPERIMENTAL
Drug: Fluticasone Propionate/Formoterol Fumarate

6

ACTIVE COMPARATOR
Drug: Formoterol Fumarate

7

PLACEBO COMPARATOR
Drug: Placebo

Interventions

Inhalation Solution

6

Inhalation Solution

7

Eligibility Criteria

Age40 Days+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Able to understand the requirements of the study and provide written informed consent
  • A clinical diagnosis of COPD
  • A current or prior history of at least 10-pack years of cigarette smoking
  • Women of child-bearing potential (WOCBP) must have a negative pregnancy test at the screening visit and agree to avoid becoming pregnant for the duration of study

You may not qualify if:

  • A clinical diagnosis of Asthma
  • Other significant disease than COPD
  • Subjects who radiation or chemotherapy within the previous 12 months
  • Subjects who had any lung resection
  • QTcB greater than 0.460 seconds
  • History of illegal drug abuse or alcohol abuse within the past 5 years

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (23)

Investigative Site

Phoenix, Arizona, United States

Location

Investigative Site

Fullerton, California, United States

Location

Investigative Site

San Diego, California, United States

Location

Investigative Site

Clearwater, Florida, United States

Location

Investigative Site

DeLand, Florida, United States

Location

Investigative Site

Tamarac, Florida, United States

Location

Investigative Site

Lawrenceville, Georgia, United States

Location

Investigative Site

Coeur d'Alene, Idaho, United States

Location

Investigative Site

Madisonville, Kentucky, United States

Location

Investigative Site

Sunset, Louisiana, United States

Location

Investigative Site

St Louis, Missouri, United States

Location

Investigative Site

Charlotte, North Carolina, United States

Location

Investigative Site

Raleigh, North Carolina, United States

Location

Investigative site

Sylvania, Ohio, United States

Location

Investigative Site

Medford, Oregon, United States

Location

Investigative Site

Easley, South Carolina, United States

Location

Investigative Site

Gaffney, South Carolina, United States

Location

Investigative Site

Greenville, South Carolina, United States

Location

Investigative Site

Greer, South Carolina, United States

Location

Investigative Site

Spartanburg, South Carolina, United States

Location

Invesigative Site

Union, South Carolina, United States

Location

Investigative Site

San Antonio, Texas, United States

Location

Investigative Site

Spokane, Washington, United States

Location

MeSH Terms

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

FluticasoneFormoterol Fumarate

Condition Hierarchy (Ancestors)

Lung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

AndrostadienesAndrostenesAndrostanesSteroidsFused-Ring CompoundsPolycyclic CompoundsEthanolaminesAmino AlcoholsAlcoholsOrganic ChemicalsAmines

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 21, 2010

First Posted

July 23, 2010

Study Start

August 1, 2010

Primary Completion

August 1, 2010

Study Completion

October 1, 2011

Last Updated

May 27, 2013

Record last verified: 2013-05

Locations